PubRank

Xiaodong Xiao

Author PubWeight™ 28.46‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 2002 3.08
2 Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006 2.00
3 Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006 1.90
4 Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003 1.87
5 Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 2004 1.80
6 Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 2007 1.76
7 Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006 1.43
8 Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008 1.25
9 A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 2004 1.07
10 Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol Cell Biol 2005 1.06
11 A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009 1.05
12 Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003 1.04
13 Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 2010 1.02
14 The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2005 1.00
15 Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther 2009 0.98
16 Evidence for CD4-enchanced signaling through the chemokine receptor CCR5. J Biol Chem 2003 0.95
17 Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther 2005 0.85
18 Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. Expert Rev Anti Infect Ther 2006 0.85
19 Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Exp Mol Pathol 2010 0.84
20 Construction of a human antibody domain (VH) library. Methods Mol Biol 2009 0.83
21 Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension 2004 0.79
22 Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4. JCI Insight 2017 0.77
23 Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody. MAbs 2010 0.75
24 Differences between CEM and human peripheral blood T lymphocytes in cAMP-dependent HIV viral fusion and CXCR4 expression. Exp Mol Pathol 2002 0.75